Catalog4 refs
ACE-031 (ACVR2B-Fc)
Muscle & PerformanceResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
MusclesCirculationSkin
Overview
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia. In healthy volunteers, a single dose produced significant increases in lean mass and reductions in fat mass within 29 days.
Primary Uses
Muscle hypertrophy
Muscular dystrophy (DMD)
Muscle wasting / cachexia
Fat loss
Bone density improvement
Protocol Reference
Dose
0.5-3 mg/kg IV every 2 weeks (clinical research doses only)
Frequency
Every 2 weeks
Half-life
12-15 days
Route
IV infusion · SubQ
Evidence
Emerging
Research Models
Human
Also in Muscle & Performance